Uses of Ropinol: - Parkinson's disease - Restless leg syndrome Parkinson's disease, Restless leg syndrome Lactation.

Antiparkinson drugs

Ropinirole binds the dopamine receptors D3 and D2. Although the precise mechanism of action of ropinirole as a treatment for Parkinson's disease is unknown, it is believed to be related to its ability to stimulate these receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that ropinirole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum.

How to use Ropinirole: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Ropinirole is to be taken with food. Administration: May be taken with or without food. May be taken w/ meals to reduce occurrence of nausea. Adult Dose: Oral As monotherapy in Parkinson's disease Adult: Initially, 250 mcg tid, may increase by 750 mcg at wkly intervals for the first 4 wk. Subsequent increments can be made in steps of 1.5 mg at wkly intervals up to 9 mg/day, then in steps of 3 mg at wkly intervals. Usual dose ranges from 3-9 mg daily. Max: 24 mg/day. Higher dose may be necessary if used in conjunction with levodopa. Gradual withdrawal is recommended. Restless leg syndrome Adult: Initially, 250 mcg daily for 2 days, taken 1-3 hr before bedtime. May increase to 500 mcg daily for the next few days. Subsequent increments may be made in steps of 500 mcg at wkly intervals until 3 mg daily is reached. Max: 4 mg daily. Hepatic impairment: Dosing adjustments may be required.

Inhibitors of CYP1A2 e.g. cimetidine, ciprofloxacin, erythromycin, fluvoxamine, isoniazid, ritonavir and zileuton may increase serum concentrations of ropinirole. Oestrogens and tobacco smoking may decrease clearance of ropinirole. Efficacy may be reduced by dopamine antagonists such as phenothiazines and metoclopramide.

Lactation.

Common - Headache - Dizziness - Fainting - Sleepiness - Vomiting - Weakness - Nausea - Edema (swelling) - Abnormality of voluntary movements - Indigestion - Hallucination - Confusion - Viral infection >10% Nausea (40-60%),Dizziness (6-40%),Somnolence (11-40%),Syncope (1-12%),Vomiting (12%),Fatigue (8-11%),Viral infection (11%),Dyspepsia (10%) 1-10% Hypertension (5%),Flushing (3%),Orthostasis (1-6%),Chest pain (4%),Palpitation (3%),Extrasystoles (2%),Tachycardia (2%),Hyperhidrosis (3%),Abnormal pain (3-7%),Anorexia (4%),Flatulence (3%),Malaise (3%),Hypoesthesia (4%),Urinary tract infection (5%),Impotence (3%),Alkaline phosphatase (3%),Abnormal vision (6%),Xerophthalmia (2%),Increased diaphoresis (3-6%) <1% Agitation,Aneurysm,Aphasia,Bradycardia,Cardiac arrest,Valvulopathy,Cellulitis,Colitis,Delusion,Delirium,Diaphoresis,Dyspnea,Ulceration,Glaucoma,Psychotic-like behavior,Impulse control/compulsive behavior,Withdrawal-emergent hyperpyrexia and confusion,Melanoma,Fibrotic complications

Pregnancy: Pregnancy category C. There are no adequate and well-controlled studies using Ropinirole in pregnant women. Ropinirole should be used during pregnancy only if the potential benefit outweighs the potential risk of the fetus.Nursing Mothers: Ropinirole inhibits prolactin secretion in humans and could potentially inhibit lactation. Because of the potential for serious adverse reactions in nursing infants from Ropinirole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother

Precaution: Pregnancy. May impair ability to drive or operate machinery. Withdrawal should be gradual. Hepatic or renal impairment. May cause daytime sleepiness or episodes of falling asleep during activities. May cause or worsen pre-existing dyskinesia.

Symptoms include nausea, vomiting, visual hallucinations, hyperhidrosis, asthenia and nightmares. General supportive measures and monitoring of vital signs are recommended. May consider gastric lavage.

Protect from light and moisture, store below 25°C. Keep out of the reach of children.

Antiparkinson drugs

Ropinirole is a non-ergot dopamine D2-agonist with similar actions to those of bromocriptine. It is used in the management of Parkinson's disease, either alone or as an adjunct to levodopa.

Pregnancy category C. There is no adequate and well-controlled studies in pregnant women. It should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. Ropinirole inhibits prolactin secretion in human and could potentially inhibit lactation.